Literature DB >> 18922343

Endoscopic management of subglottic stenosis.

Sivi Bakthavachalam1, John E McClay.   

Abstract

OBJECTIVES: Determine the effectiveness of endoscopic surgical treatment of subglottic stenosis (SGS) in children as a primary surgical modality to prevent laryngotracheal reconstruction (LTR) and as treatment for restenosis following primary LTR to prevent revision LTR. PATIENTS: Children undergoing various endoscopic surgical treatments from 1989 to 2006 for SGS.
RESULTS: The number of children and success rates per grade of SGS and the number of procedures required to produce a successful result in 29 children initially managed endoscopically included grade I, three of three (100%), 1.3 procedures; grade II, eight of nine (88%), 2.6 procedures; and grade III, 13 of 17 (76%), 3.5 procedures. Of 102 patients undergoing open LTR, 56 of 102 required endoscopic interventions and 41 of 56 (73%) children were treated successfully.
CONCLUSION: Endoscopic intervention can be used to manage SGS either as a primary intervention or to treat reobstruction and restenosis following an open reconstructive procedure. Success rates decline as the severity of stenosis increases.

Entities:  

Mesh:

Year:  2008        PMID: 18922343     DOI: 10.1016/j.otohns.2008.07.024

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  2 in total

1.  Rigid dilatation of pediatric laryngotracheal stenosis as an adequate alternative to balloon dilatation.

Authors:  Daniel Yafit; Oren Cavel; Omer J Ungar; Oshri Wasserzug; Yael Oestreicher-Kedem; Anna Shklovsky-Kordi; Ari DeRowe
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-08-11       Impact factor: 2.503

2.  Outcomes of balloon dilation for paediatric laryngeal stenosis.

Authors:  Giovanna Cantarella; Michele Gaffuri; Sara Torretta; Simona Neri; Maria Teresa Ambrosini; Alessandra D'Onghia; Lorenzo Pignataro; Kishore Sandu
Journal:  Acta Otorhinolaryngol Ital       Date:  2020-10       Impact factor: 2.124

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.